Case Report

Rapid Weight Loss and Severe Failure to Thrive Mimicking Lipodystrophy Syndrome in a 1-Year-Old Taiwanese Girl with Costello Syndrome

Yu-Min Syu 1,2, Hung-Chang Lee 3,4,5, Jui-Hsing Chang 4,5, Chung-Lin Lee 2,6,7, Chih-Kuang Chuang 8,9, Huei-Ching Chiu 2, Ya-Hui Chang 2,6, Hsiang-Yu Lin 2,5,8,10,11,12, and Shuan-Pei Lin 2,4,6,8,12,13

1 Department of Pediatrics, Far Eastern Memorial Hospital, New Taipei City 22021, Taiwan; b101098040@tmu.edu.tw
2 Division of Genetics and Metabolism, Department of Pediatrics, MacKay Memorial Hospital, Taipei 10449, Taiwan; clamppcg@yahoo.com.tw (C.-L.L.); g880a01@mmh.org.tw (H.-C.C.); wish1001026@gmail.com (Y.-H.C.)
3 Division of Gastroenterology and Nutrition, Department of Pediatrics, MacKay Children’s Hospital, Taipei 10449, Taiwan; ped2435@mmh.org.tw
4 Department of Medicine, MacKay Medical College, New Taipei City 25245, Taiwan; pchhang90@yahoo.com.tw
5 Department of Pediatrics, MacKay Children’s Hospital, Taipei 10449, Taiwan
6 Department of Rare Disease Center, MacKay Memorial Hospital, Taipei 10449, Taiwan
7 Institute of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei 11221, Taiwan
8 Division of Genetics and Metabolism, Department of Medical Research, MacKay Memorial Hospital, Taipei 10449, Taiwan; mmhcck@gmail.com
9 College of Medicine, Fu-Jen Catholic University, Taipei 24205, Taiwan
10 Department of Childhood Care and Education, MacKay Junior College of Medicine, Nursing and Management, Taipei 11260, Taiwan
11 Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan
12 Department of Infant and Child Care, National Taipei University of Nursing and Health Sciences, Taipei 11219, Taiwan
* Correspondence: lxc46199@ms37.hinet.net (H.-Y.L.); 4535lin@gmail.com (S.-P.L.); Tel.: +886-2-2543-3535 (ext. 3089) (H.-Y.L.); +886-2-2543-3535 (ext. 3090) (S.-P.L.); Fax: +886-2-2543-3642 (S.-P.L.)

Abstract: Costello syndrome (CS) is a type of RASopathy caused mainly by de-novo heterozygous pathogenic variants in the HRAS gene located on chromosome 11p15.5. The phenotype of CS is characterized by prenatal overgrowth, postnatal failure to thrive, curly or sparse fine hair, coarse facial features, and multisystem involvement, including cardiovascular, endocrine, and gastroenterological disorders. We present a one-year-old girl with rapid weight loss and severe failure to thrive. She had gastroesophageal reflux at the age of four months with subsequent rapid weight loss. The loss of fat tissue over the whole body, refractory to a hypercaloric diet, mimicked the presentation of progressive lipodystrophy and masked the dysmorphic features of CS. The final diagnosis of CS was made by whole exome sequencing, which demonstrated a hot-spot, heterozygous pathogenic variant in the HRAS gene (c.34G > A, rs104894229). Our patient illustrates that the excessive energy needs in CS patients may lead to severe failure to thrive and cause challenges in diagnosing CS. This case also highlights the importance of recognizing CS in patients with a history of prenatal overgrowth, polhydramnios presenting with severe failure to thrive refractory to pharmacotherapy and tube feeding.

Keywords: Costello syndrome; RASopathy; failure to thrive; dysmorphism; nutritional status
1. Introduction

RASopathies are a group of rare genetic diseases caused by germline mutations in the RAS pathway genes, which play important roles in cellular growth and differentiation. Collectively, RASopathies represent one of the largest groups of multiple congenital anomaly syndromes, including Costello syndrome (CS), Noonan syndrome, Legius syndrome, LEOPARD syndrome, neurofibromatosis1, and cardio-facio-cutaneous syndrome. These syndromes have recognizable and overlapping phenotypic features and associated anomalies, such as cutaneous lesions, cardiac defects, and cancer susceptibility. Making an early clinical diagnosis can be challenging because of absent or uncharacteristic craniofacial features and because the complete clinical picture may evolve only with time [1,2]. Herein, we report a one-year-old girl presenting with complicated clinical manifestations, including gastrointestinal dysfunction, rapid weight loss, and severe failure to thrive, mimicking lipodystrophy. The dysmorphic features were not distinct until her nutritional status had been optimized after the molecular diagnosis of CS, which was further affirmed by the transformation of the clinical picture.

2. Clinical Report

A one-year-old Taiwanese girl presented to our clinic for a second opinion due to severe failure to thrive. She was the first child of healthy non-consanguineous parents. According to previous medical records, her mother received regular prenatal examinations. The pregnancy was complicated by severe polyhydramnios, which was treated three times by amnioreduction. Amniocentesis revealed a normal female karyotype, and array comparative genomic hybridization of amniotic fluid showed negative findings. On prenatal ultrasound, polyhydramnios and increased abdominal circumference were noted. She was born at 34 weeks and 5 days of gestation by cesarean section at a tertiary referral center. Her birth weight was 3.18 kg (90–97th centile for gestational age), length 48 cm (50–75th centile), and occipitofrontal head circumference (OFC) 35.8 cm (>90th centile). The Apgar scores were 8 at 1 min and 9 at 5 min. She presented with general swelling and a high-arched palate, relatively large mouth, and small thoracic cavity without other distinct facial dysmorphisms. Immediately after birth, she required ventilatory support for respiratory distress and was hospitalized for 20 days. Echocardiography revealed biventricular hypertrophy with blocked premature atrial complexes, and propranolol was given thereafter. Her karyotype was normal (46,XX), and rare metabolic disorder work-up revealed negative findings. The post-discharge course was smooth, and her development was within normal limits before four months of age.

At the age of four months, she began to have diarrhea and gastroesophageal reflux (GER). Proton pump inhibitors along with prokinetic agents were prescribed, however, poor appetite, frequent regurgitation with intermittent abdominal bloating, and constipation persisted. Her body weight dropped dramatically from 4.6 kg to 3.6 kg within two months, even under medical care.

At the age of one year, she showed weight loss of 3.6 kg (<3rd centile) with a body length of 56.3 cm (<3rd centile) and OFC of 40.5 cm (<3rd centile). Serial body weight, length, and OFC measurements are shown in Figure 1. Informed consent was obtained for clinical photographs and publication from her parents.
Figure 1. The patient’s serial body weight (A), length (B), and OFC (C) measurements (in pink) compared to the normative growth chart of normal individuals and CS patients. Adapted with permission from Ref. [3]. 2012, Karen W. Gripp. OFC, occipitofrontal head circumference; CDC: Centers for Disease Control and Prevention; CS: Costello syndrome.
A physical examination showed a child with a severely wasting appearance and a
gestalt of generalized lipodystrophy (Figure 2A). She had sparse hair, frontal bossing,
deep-set eyes, relatively large mouth, skeleton-like cheeks with prominent masticatory
muscles, loose and thin skin with prominent superficial veins, and very thin subcutaneous
fat tissue and thin muscle layers. A neurodevelopmental examination revealed hypotonia
and global delay with poor head control, absence of rolling, and language development.
She had oro-motor dysfunction and was fed 450–500 kcal per day via a nasogastric tube
(NG tube), corresponding to 130% of the daily calorie requirement for her ideal body
weight. A cardiovascular examination, including electrocardiogram (ECG), Holter moni-
toring, and echocardiogram, showed a slightly thickened interventricular septum, but
other findings were normal. An abdominal examination, including abdominal radiography
and sonography, showed diffuse gaseousness with bowel dilatation, indicating an ileus
pattern. Stool analysis results were unremarkable. A lower gastrointestinal (GI) series
raised the suspicion of Hirschsprung’s disease, however, a rectal suction biopsy showed
the presence of ganglion cells and staining for acetylcholinesterase was unremarkable.
Her overall clinical assessment raised the suspicion of lipodystrophy. During the hos-
pitalization, transient hypoglycemia was noted once, while her growth hormone (GH),
cortisol, and insulin levels were normal. Her thyroid function, immunoglobulin profiles,
lipid profiles, and metabolic investigations were also unremarkable. These findings did
not indicate a syndromal diagnosis, and therefore, exome sequencing was arranged. We
collected peripheral blood from the patient, and the sample was extracted by CatchGene
Cell/Blood DNA Kit (CatchGene, New Taipei City, Taiwan). The whole exome sequencing
was performed by IlluminaNextSeq 500 system platform with IDT xGenexome research
panel v2 reagent chemistry (IDT, Coralville, IA, USA), usingNextSeq 500/550 Mid Output
Kit v2.5 (300 Cycles). After sequencing was completed, the FASTQ file was uploaded to the
Illuminabasespace and processed with DRAGEN Enrichment (Illumina Inc., San Diego, CA,
USA) to generate the VCF file. The variant filtering was carried out using Illuminabasespace
variant interpreter. The variants were filtered by the following criterion: (1) Population
frequency (in both general population and East Asian subgroup) below 0.01 in 3 different
databases: The Genome Aggregation Database (http://gnomad.broadinstitute.org/),
the Exome Aggregation Consortium (http://exac.broadinstitute.org/), the 1000 Genomes
Project (http://browser.1000genomes.org), accessed all on 4 October 2021, (2) Sequencing
depth >10 and the alternate variant ≥ 0.25, (3) Classified as pathogenic, likely pathogenic or
uncertain significances. We confirmed the identified variants via Sanger sequencing and
interpreted the variants using the guidelines of the American College of Medical Genetics
and Genomics (ACMG) [4].

The results of exome sequencing showed a de novo, heterozygous HRAS missense
mutation c.34G > A (p.Gly12Ser), which we confirmed via Sanger sequencing, indicative of
CS [5]. The variant was reported in ClinVar as a hot-spot mutation in HRAS gene and was
classified as pathogenic. There was no distinct facial gestalt of CS except for sparse hair and
relatively large mouth at the time of molecular diagnosis.

Because of the persistent GER complicated with Sandifer syndrome, laparoscopic
fundoplication and gastrostomy for nutritional support were done at the age of one year
and three months. A small liver with nearly no fat tissue was seen in intraoperative
laparoscopy. However, the lack of weight gain persisted after the intervention, and pe-
ripheral parenteral nutrition was, therefore, administered. With optimization of her nutri-
tional status with peripheral parenteral nutrition, she achieved a body weight of 4.7 kg at
one year and five months and 7.3 kg (5–50th centile for children with CS) at one year and six
months. Downslanting eyes, low nasal bridge, thick lips, wide nostrils, and curly, sparse,
thin hair developed, which were compatible with the classical dysmorphism of CS. The
transformation of her craniofacial features is shown in Figure 2.
Figure 2. Craniofacial features of the patient. (A) At the age of one year, with a body weight of 3.6 kg. (B) At the age of one year and five months, with a body weight of 4.7 kg. Low nasal bridge and thick lips were more distinct. (C) At the age of one year and six months, with a body weight of 7.4 kg. Downslanting eyes, low nasal bridge, thick lips, wide nostrils and curly, sparse, thin hair were presented.
3. Discussion

Costello syndrome (CS) is a type of RASopathy caused mainly by de-novo heterozygous pathogenic variants in the HRAS gene, which is located on chromosome 11p15.5. The estimated birth prevalence of CS is 1:380,000–1,290,000 [6,7]. The phenotype of CS is characterized by prenatal polyhydramnios, overgrowth, postnatal failure to thrive, relative macrocephaly, curly or sparse fine hair, large mouth with thick lips, coarse facial features, hypotonia with developmental delay, and multisystem involvement, including cardiovascular, endocrine, and gastroenterological disorders [8,9].

Cardiovascular disease is present in 85% of individuals with CS, including hypertrophic cardiomyopathy (HCM), congenital heart defects, dysrhythmias and/or hypertension. HCM accounts for 75% of cardiovascular pathology, and the clinical course varies from a rare severe neonatal lethal form to the typical mild to moderate form of HCM seen in the majority of cases [8]. Chronic or progressive hypertrophy has been reported in 37% of affected individuals, stable disease in 25%, and improvement or resolution in 14% [10]. Given the risk of cardiovascular disorders, screening and annual follow-up with echocardiography, ECG, and Holter monitoring are warranted throughout life.

Endocrine disorders common in children with CS include hypoglycemia, GH deficiency, and problems with puberty. Neonates and infants are at high risk of hyperinsulinemic hypoglycemia, while infants or young individuals often present with low serum glucose due to GH deficiency.

Feeding difficulties, poor suction power, severe GER, and failure to thrive are almost universal clinical manifestations of CS, and alternative feeding methods have been suggested [8]. For example, in a small cohort of 20 infants with CS, 95% received NG tube placement, and 35% required gastrostomy tube (G-tube) placement. Treatment with proton pump inhibitors and prokinetic agents should be considered for gastroenterological disorders. The degree of failure to thrive is most severe at 12 months of age, and the body weight of most children with CS at that time period is below the 5th percentile compared to the general population [3]. The mean weight at one year of age has been reported to be 6.7 kg [11]. The reasons for failure to thrive are likely multifactorial, and may involve feeding difficulties, poor nutritional intake, hormonal abnormalities, increased resting energy expenditure, and dysregulated central control of body weight via leptin signaling in the hypothalamus [12,13]. Several studies have reported that CS patients follow a natural growth history in weight and height regardless of whether a normal or hypercaloric diet is given [11,13]. In addition, it has also been reported that poor nutritional status may obscure the classic facial gestalt of CS (downslanting eyes, low nasal bridge, full cheeks, thick lips, etc.) and cause difficulties in making a diagnosis [12].

Our patient presented with GI dysfunction and feeding difficulty at four months of age, both of which contributed to rapid weight loss and severe failure to thrive. Her body weight was below the 5th centile compared to the normative growth curve for CS patients [3]. Feeding by an NG tube and then a G-tube with adequate daily calorie supplement under medical care was tried, but the growth deficiency persisted. The disproportionate calorie needs may have indicated increased resting metabolism in our patient. While previous studies have documented an improvement in weight gain with either NG tube or G-tube feeding after one year of age, our patient had persistent growth deficiency, and only peripheral parenteral nutrition helped the condition. Her refractory failure to thrive and rapid loss of fat mimicked the presentation of lipodystrophy, masked the dysmorphic features of CS, and complicated the clinical picture. The low nasal bridge and coarse facial features were not obvious compared to her sunken cheeks and eyeballs. In addition, her symmetric growth deficiency with microcephaly was not compatible with the typical feature of relative macrocephaly in patients with CS. Her hypotonia and developmental delay were distinct but initially attributed to muscle wasting. The diagnosis of CS is difficult in early infancy because some characteristics may only evolve with time [1].

Besides the non-specific wasting appearance, our patient had atypical cardiovascular presentations that further complicated the diagnosis of CS. The ECG and echocardiography
on presentation only showed a slightly thickened interventricular septum, but not the typical feature of HCM or arrhythmia. However, tracing back her medical history, cardiovascular disorders which may have indicated CS, such as biventricular hypertrophy and blocked premature atrial complexes, were documented after birth but resolved within one year. About 68% of CS patients with HCM have a progressive or stable clinical course, and 14% have resolution and about 70% of CS patients with atrial arrhythmias have a stable or resolved course [10]. In addition, our patient had a prenatal history of polyhydramnios and a past history of being large for gestational age with general edema, which are typical presentations of CS. A comprehensive medical record review of the cardiovascular system and pre- and postnatal history of a patient may be of value in the diagnosis of CS besides a single evaluation at presentation.

The final diagnosis of CS was made by whole exome sequencing, which demonstrated a hot-spot, heterozygous pathogenic variant in the HRAS gene (c.34G > A, rs104894229). The clinical picture was not completely compatible with the molecular diagnosis until her condition improved and the dysmorphisms developed over time. Our patient illustrates that excessive energy needs in CS patients may lead to severe failure to thrive that mimics the presentation of lipodystrophy and causes challenges in diagnosing CS. In infants presenting with lipodystrophic features with an initial onset of GI disorders and unremarkable metabolic and lipid profiles [14], it is important for pediatricians to take CS into consideration and search for subtle clues that may be disguised by the appearance of malnutrition. Our case also highlights the importance of recognizing CS in patients with a history of prenatal overgrowth, polyhydramnios presenting with severe failure to thrive refractory to pharmacotherapy and tube feeding. The early diagnosis of CS may provide clinical insights indicating the need for alternative feeding routes or peripheral parenteral nutritional support. Optimized treatment strategies for children with CS may lead to better development.

**Author Contributions:** Y.-M.S. drafted the manuscript. H.-C.L., J.-H.C. and S.-P.L. participated in the patient’s follow-up and helped in drafting the manuscript. C.-K.C., H.-C.C. and Y.-H.C. performed biochemical analyses and revised the manuscript. C.-L.L., H.-Y.L. and S.-P.L. were responsible for manuscript revision. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by research grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST-111-2811-B-195-001, MOST-110-2314-B-195-010-MY3, MOST-110-2314-B-195-014, MOST-110-2314-B-195-029) and MacKay Memorial Hospital (MMH-E-111-13, MMH-E-110-16, MMH-E-109-16, and MMH-E-108-16). The authors confirm independence from the sponsors.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of MacKay Memorial Hospital approved this study (22MMHS019e, approval date: 24 March 2022).

**Informed Consent Statement:** Written informed consent was obtained from the parents of the patient.

**Acknowledgments:** We acknowledge the participation of study patients and their families.

**Conflicts of Interest:** The authors declare that they have no competing interest.

**Abbreviations**

- OFC: occipitofrontal head circumference
- GER: gastroesophageal reflux
- NG tube: nasogastric tube
- ECG: electrocardiogram
- GI: gastrointestinal
- GH: growth hormone
- CS: Costello syndrome
- HCM: hypertrophic cardiomyopathy
- G-tube: gastrostomy tube
References

1. Kargl, S.; Meissl, M.; Pumberger, W. Early postnatal diagnosis of Costello syndrome. *Klin. Padiatr.* **2014**, *227*, 45–47. [CrossRef]
2. Lee, C.; Tan, L.T.H.; Lin, H.; Hwu, W.; Lee, N.; Chien, Y.; Chuang, C.; Wu, M.; Wang, J.; Chu, S.; et al. Cardiac manifestations and gene mutations of patients with RASopathies in Taiwan. *Am. J. Med. Genet. Part A* **2020**, *182*, 357–364. [CrossRef] [PubMed]
3. Sammon, M.R.; Doyle, D.; Hopkins, E.; Sol-Church, K.; Stabley, D.L.; McGreedy, J.; Schulze, K.; Alade, Y.; Hoover-Fong, J.; Gripp, K.W. Normative growth charts for individuals with Costello syndrome. *Am. J. Med. Genet. Part A* **2012**, *158A*, 2692–2699. [CrossRef] [PubMed]
4. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* **2015**, *17*, 405–423. [CrossRef]
5. Gripp, K.W.; Rauen, K.A. Costello Syndrome. In *GeneReviews*; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Anemiya, A., Eds.; University of Washington: Seattle, WA, USA, 2006.
6. Tajan, M.; Pacaud, R.; Branka, S.; Edouard, T.; Yart, A. The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway. *Endocr. Rev.* **2018**, *39*, 676–700. [CrossRef]
7. Abe, Y.; Aoki, Y.; Kuriyama, S.; Kawame, H.; Okamoto, N.; Kurosawa, K.; Ohashi, H.; Mizuno, S.; Ogata, T.; Kure, S.; et al. Prevalence and clinical features of Costello syndrome and cardio-facio-cutaneous syndrome in Japan: Findings from a nationwide epidemiological survey. *Am. J. Med. Genet. Part A* **2012**, *158A*, 1083–1094. [CrossRef]
8. Gripp, K.W.; Morse, L.A.; Axelrad, M.; Chatfield, K.C.; Chidekel, A.; Dobyns, W.; Doyle, D.; Kerr, B.; Lin, A.E.; Schwartz, D.D.; et al. Costello syndrome: Clinical phenotype, genotype, and management guidelines. *Am. J. Med. Genet. Part A* **2019**, *179*, 1725–1744. [CrossRef]
9. Digilio, M.C.; Sarkozy, A.; Capolino, R.; Testa, M.B.C.; Esposito, G.; De Zorzi, A.; Cutrera, R.; Marino, B.; Dallapiccola, B. Costello syndrome: Clinical diagnosis in the first year of life. *Eur. J. Pediatr.* **2008**, *167*, 621–628. [CrossRef] [PubMed]
10. Lin, A.E.; Alexander, M.E.; Colan, S.D.; Kerr, B.; Rauen, K.A.; Noonan, J.; Baffa, J.; Hopkins, E.; Sol-Church, K.; Limongelli, G.; et al. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: A Ras/MAPK pathway syndrome. *Am. J. Med. Genet. Part A* **2011**, *155*, 486–507. [CrossRef] [PubMed]
11. Leoni, C.; Giorgio, V.; Onesimo, R.; Kuczynska, E.; Zampino, G. Impact of Costello syndrome on growth patterns. *Am. J. Med. Genet. Part A* **2020**, *182*, 2797–2799. [CrossRef] [PubMed]
12. Chiu, A.T.; Zhu, L.; Mok, G.T.; Leung, G.K.; Chow, C.; Chung, B.H. Before and after—Nutritional transformation of dysmorphism in a case of Costello syndrome. *Eur. J. Med. Genet.* **2016**, *59*, 573–576. [CrossRef]
13. Leoni, C.; Onesimo, R.; Giorgio, V.; Diamanti, A.; Giorgio, D.; Martini, L.; Rossodivita, A.; Tartaglia, M.; Zampino, G. Understanding Growth Failure in Costello Syndrome: Increased Resting Energy Expenditure. *J. Pediatr.* **2016**, *170*, 322–324. [CrossRef]
14. Brown, R.J.; Araujo-Vilar, D.; Cheung, P.T.; Dunger, D.; Garg, A.; Jack, M.; Mungai, L.; Oral, E.A.; Patni, N.; Rother, K.I.; et al. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. *J. Clin. Endocrinol. Metab.* **2016**, *101*, 4500–4511. [CrossRef]